NPS Pharma and VIMAC Ventures locate at MaRS, a major new research and enterprise center in Toronto

TORONTO May 17, 2004 Salt Lake City-based NPS Pharmaceuticals and Boston-based VIMAC Ventures announced today that they plan to locate key business and research facilities to the new MaRS (Medical and Related Sciences) Discovery District biosciences research and commercialization hub in downtown Toronto. These firms have selected MaRS as the ideal global destination to pursue research and commercial opportunities in the fast-emerging medical and related technology fields.

MaRS Centre will become the primary location for NPS's research and development activities in Canada while VIMAC, a venture capital firm active in biosciences, will establish a business office in the center for the firm's VIMAC Milestone Medica Fund.

To date, 12 organizations have signed agreements to lease almost 600,000 square feet of the 700,000 square feet available in Phase One of MaRS Centre, including CMDF (Canadian Medical Discoveries Fund), the Hospital for Sick Children, MDS Inc. (MDS Sciex Division), RBC Technology Ventures Inc., RBC Financial Group, University Health Network and the Blueprint Initiative.

"With its proximity to some of the leading minds and institutions in Toronto's bioscience cluster, MaRS is the perfect site for our drug research and development work in Canada," says Dr. Hunter Jackson, Chairman, President and CEO of NPS. "Our presence at MaRS underscores our commitment to research and development in Canada and the importance of this new facility to our future business success."

NPS will initially move approximately 70 researchers into a wet lab facility at MaRS, with plans to add another 50 scientists over time. The company has been mining a wealth of research from the Toronto area for many years.

VIMAC chose MaRS to expand the firm's North American reach because it provides one of the most dynamic opportunities for investment in biosciences, according to Dana Ono, Managing Director, VIMAC Milestone Medica Fund.



Page: 1 2 3 4

Related biology news :

1. Warren Pharmaceuticals publishes results of preclinical evaluation
2. Pharmacogenomics could replace trial-and-error with science from the human genome
3. Cyclis Pharmaceuticals reports studies defining new mechanism for potential cancer therapies
4. Relapse or remission? Pharmacogenomics draws the fine line
5. Pharmaceutical smart bomb targets cancer cells
6. Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals
7. Science and Amersham Pharmacia Biotech grand prize: "jumping DNA" discovery explains immune system evolution
8. Pharmaceutical and personal care products: What happens when they enter the environment - an emerging concern
9. Science and Amersham Pharmacia Biotech award Young Scientist Prize
10. Researchers, Regulators, Industry, Consumer Advocates Gather to Discuss Critical Issues Facing the Pharmaceutical Industry
11. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus

Post Your Comments:

(Date:8/21/2020)... ... 18, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology ... and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application ... COVID-19. Approval of this IND allows Sentien to initiate a Phase 1/2 study ...
(Date:8/12/2020)... ... August 12, 2020 , ... Mosio ... are ideal for public health agencies of all sizes. With a focus on ... at-risk individuals find appropriate health care, Mosio helps public health departments automate communications ...
(Date:7/31/2020)... ... July 30, 2020 , ... BioFactura, ... contract awarded by the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) ... develop, optimize, and scale-up a highly efficient mammalian cell culture-based bioprocess suitable to ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 30, 2020 , ... Alucio™, ... announced the release of its signature product called Beacon - a content ... other field medical professionals. , Beacon helps MSLs streamline communication and ...
(Date:7/18/2020)... ... ... “We are thrilled to deliver this new technology to the industry” said Matt Hundt, ... market and we were pleased that the IFT jury recognized that.” reFRESH™ couples the ... natural way to extend the shelf life and improve the safety of perishable foods ...
(Date:7/10/2020)... ... July 08, 2020 , ... ... products, announces a significant expansion of laboratory operations through its COVID-19 testing ... implementing testing programs. , Bode-CARES provides a turnkey solution that ...
(Date:7/10/2020)... ... 09, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology ... R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will ... SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine at the ...
Breaking Biology Technology:
Cached News: